Wall Street analysts predict that ContraFect Corp (NASDAQ:CFRX) will announce earnings per share of ($0.10) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ContraFect’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.11). ContraFect posted earnings per share of ($0.12) in the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The firm is expected to report its next earnings results on Thursday, March 21st.
On average, analysts expect that ContraFect will report full year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.68) to ($0.67). For the next fiscal year, analysts expect that the firm will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow ContraFect.
ContraFect (NASDAQ:CFRX) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.04.
Separately, ValuEngine lowered ContraFect from a “buy” rating to a “hold” rating in a report on Thursday, December 6th.
Shares of ContraFect stock remained flat at $$0.55 during trading on Friday. The stock had a trading volume of 837,472 shares, compared to its average volume of 1,440,767. The firm has a market capitalization of $43.52 million, a price-to-earnings ratio of -1.48 and a beta of 0.37. ContraFect has a twelve month low of $0.42 and a twelve month high of $2.93.
In other news, major shareholder Fosun Pharmaceutical Shanghai sold 600,000 shares of the company’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $2.04, for a total transaction of $1,224,000.00. Following the completion of the sale, the insider now directly owns 7,900,000 shares of the company’s stock, valued at $16,116,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Trellus Management Company LLC lifted its stake in ContraFect by 88.8% in the 3rd quarter. Trellus Management Company LLC now owns 83,955 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 39,492 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in ContraFect by 108.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 167,182 shares of the biotechnology company’s stock worth $346,000 after acquiring an additional 86,848 shares in the last quarter. Renaissance Technologies LLC lifted its stake in ContraFect by 40.6% in the 2nd quarter. Renaissance Technologies LLC now owns 200,500 shares of the biotechnology company’s stock worth $443,000 after acquiring an additional 57,900 shares in the last quarter. AXA lifted its stake in ContraFect by 196.0% in the 3rd quarter. AXA now owns 1,664,781 shares of the biotechnology company’s stock worth $3,446,000 after acquiring an additional 1,102,264 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in ContraFect by 24.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 512,940 shares in the last quarter. 57.34% of the stock is owned by hedge funds and other institutional investors.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Read More: Leveraged Buyout (LBO) Explained
Get a free copy of the Zacks research report on ContraFect (CFRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.